ASX/Media Release

RESULTS OF ANNUAL GENERAL MEETING

SYDNEY, AUSTRALIA – 27 November 2026 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or the "Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that the results of its Annual General Meeting (AGM) are set out in the attached document in accordance with section 251AA(2) of the *Corporations Act 2001* (Cth) and Listing Rule 3.13.2.

All resolutions were decided by way of poll. All resolutions were passed.

In accordance with Listing Rule 3.13.2(f), Immutep advises that at least 25% of the votes cast on Resolution 1 were against the adoption of the Remuneration Report for the year ended 30 June 2026, which constitutes a "first strike" for the purposes of section 250U of the *Corporations Act*.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com

U.S. Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com

This announcement was authorised for release by Indira Naidu, Company Secretary of Immutep Limited.

Immutep Limited
Annual General Meeting
Friday, 27 November 2026
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	**Resolution Type**	**For**	**Against**	**Proxy's Discretion**	**Abstain**	**For**	**Against**	**Abstain***	**Carried / Not Carried**	
1. Adoption of Remuneration Report	Ordinary	84,576,121 49.70%	82,770,674 48.64%	2,839,829 1.67%	2,310,017	87,636,731 51.43%	82,778,174 48.57%	2,310,017	Carried	Yes
2. Re-election of Director – Dr Russell Howard	Ordinary	127,897,126 62.56%	73,863,688 36.13%	2,664,210 1.30%	2,999,694	130,789,617 63.91%	73,863,688 36.09%	2,999,694	Carried	n/a
3. Re-election of Director – Ms Elisabeth (Lis) Boyce	Ordinary	189,684,902 93.42%	10,624,531 5.23%	2,729,017 1.34%	4,386,268	192,642,200 94.77%	10,624,531 5.23%	4,386,268	Carried	n/a
4. Approval of additional 10% placement capacity (Special Resolution)	Special	184,851,254 90.19%	16,621,014 8.11%	3,489,709 1.70%	2,462,741	188,561,744 91.90%	16,628,514 8.10%	2,462,741	Carried	n/a

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.